BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-702@pharmaconomics
DTSTAMP:20260707T034219Z
DTSTART;VALUE=DATE:20260531
DTEND;VALUE=DATE:20260601
SUMMARY:FENC Phase 1 — PEDMARK
DESCRIPTION:Phase 1 trial results for PEDMARK in metastatic germ cell tumor are due May 31\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1211583/000110465926046804/fencf-20260422xex99d1.htm\n\nTrack it: https://www.pharmaconomics.com/e/702
URL:https://www.pharmaconomics.com/e/702
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:FENC catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR